Develops genetic therapies for rare, often fatal diseases, focusing on inherited heart disorders and related conditions for patients with these diseases.
10-K for FY2025, filed Feb 26, 2026
Focus on cardiovascular gene therapies
The older report describes programs across blood disorders and inherited heart disease, while the latest report prioritizes its AAV cardiovascular platform and deprioritizes further work on its FA and PKD programs.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We are a clinical-stage, multi-platform biotechnology company focused on the development of first, only and best-in-class gene therapies…View ↗
Loading...